Quarterly report pursuant to Section 13 or 15(d)

NON CONTROLLING INTEREST (Details)

v3.24.2.u1
NON CONTROLLING INTEREST (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Net loss attributable to the non-controlling interest     $ (17,337) $ (2,040)
BioCorRx Pharmaceuticals, Inc [Member]        
Net loss $ (67,251) $ (1,849) $ (68,800) $ (3,296)
Average Non-controlling interest percentage of profit/losses 24.20% 24.20% 24.20% 24.20%
Net loss attributable to the non-controlling interest $ (16,275) $ (448) $ (16,650) $ (798)
Joseph DeSanto MD [Member]        
Net loss $ (1,072) $ (1,881) $ (1,964) $ (3,550)
Average Non-controlling interest percentage of profit/losses 35.00% 35.00% 35.00% 35.00%
Net loss attributable to the non-controlling interest $ (375) $ (658) $ (687) $ (1,242)